Web NewDrugInformation.com

Emete-con Drug - Emete-con The trade name of the product as shown on the labeling. Dosage - SUPPOSITORY; RECTAL The product dosage form and route separated by a semi-colon. Active Ingredient(s) - Benzquinamide Hydrochloride Multiple ingredients are in alphabetical order. Strength - EQ 100MG BASE The potency of the active ingredient(s), Benzquinamide Hydrochloride. May repeat for multiple part products. Applicant - ROERIG The firm name holding legal responsibility for Emete-con. The firm name is condensed to a maximum twenty character unique string. New Drug Application (NDA) Number - 016818 The FDA assigned number to Emete-con. Format is nnnnnn. Product Number - 006 The FDA assigned number to identify Emete-con. Each strength is a separate product. May repeat for multiple part products. Format is nnn. Therapeutic Equivalence (TE) Code - The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products. Approval Date - Approved Prior to Jan 1, 1982 The date Emete-con was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982". Reference Listed Drug (RLD) - No The pioneer or innovator of Emete-con. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No. Type - DISCN The group or category of approved drugs Emete-con is in. Format is RX, OTC, DISCN. Applicant Full Name - Roerig Div Pfizer Inc The full name of the firm holding legal responsibility for the new application of Emete-con. Emete-con Didrex 50mg Tablet; Oral Emete-con Eq 50mg Base/vial Injectable; Injection Emete-con Eq 100mg Base Suppository; Rectal Tessalon 200mg Capsule; Oral Benzaclin 5%;eq 1% Base Gel; Topical Duac 5%;eq 1% Base Gel; Topical Benzamycin 5%;3% Gel; Topical Benzamycin Pak 5%;3% Gel; Topical Erythromycin And Benzoyl Peroxide 5%;3% Gel; Topical Didrex 25mg Tablet; Oral NewDrugInformation